A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats

Human and Experimental Toxicology

Volumn 18, Issue 1, 1999, Pages 38-45

  Takizawa, T ^a   Hasimoto, K ^a   Itoh, N ^a   Yamashita, S ^a   Owen, K ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Arthropathy; Crystalluria; Fluoroquinolones; Grepafloxacin; Rat; Toxicity

Indexed keywords

CIPROFLOXACIN; ENOXACIN; GREPAFLOXACIN; LOMEFLOXACIN; OFLOXACIN; QUINOLONE; SODIUM;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTHROPATHY; ARTICLE; BODY WEIGHT; CECUM; CONTROLLED STUDY; CRYSTALLURIA; DRUG REEXPOSURE; FECES ANALYSIS; FLUID INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RAT; SODIUM URINE LEVEL; STREPTOCOCCUS PNEUMONIAE; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD CELLS; BODY WEIGHT; EATING; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT, NEWBORN; JOINT DISEASES; MALE; ORGAN SIZE; PIPERAZINES; QUINOLONES; RATS; SURVIVAL RATE; TIME FACTORS;

ANIMALIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0032934353     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032799678839310     Document Type: Article

References (29)

1. Christ W, Lehnert T, Ulbrich B. Specific toxicological aspects of the quinolones. Reviews of Infectious Diseases 1988; 10 (Suppl 1): S141-S146.
2. Mayer DG. Overview of toxicological studies. Drugs 1988; 34 (Suppl 1): 150-153.
3. Gordon HA, Nakayama S. Elevated levels of colloid osmotic pressure in cecal contents of germfree animals. Proceedings of the Society for Experimental Biology & Medicine 1975; 149: 46-49.
4. Loeschke K, Kautz U, Lohrs U. Effects of antibiotics on caecal electrolyte transport and morphology in rats: Contribution to the pathogenesis of antibiotic-associated diarrhoea. Klinische Wochenschrift 1980; 58: 383-385.
5. Loeschke K, Uhlich E, Halbach R. Caecal enlargement combined with sodium transport stimulation in rats fed with Polyethylene Glycol. Proceedings of the Society for Experimental Biology & Medicine 1973; 142: 96-102.
6. Onodera T et al. Four week oral subacute toxicity study of the synthetic antibacterial agent DL-8280 in rats. Chemotherapy 1984; 32: 1091-1104.
7. Oishi S, Oisho H, Hiraga K. The effect of food restriction for 4 weeks on common toxicity parameters in male rats. Toxicology and Applied Pharmacology 1979; 47: 15-22.
8. Scharer K. The effect of chronic underfeeding on organ weights of rats. How to interpret organ weight changes in cases of marked growth retardation in toxicity tests. Toxicology 1977; 7: 45-56.
9. Edanaga M, Kita T, Okuda K, Horizoe H. Toxicological study of bacampicillin hydrochloride. Chemotherapy 1979; 27 (Suppl 4): S17-S29.
10. Takayama S, Hirohashi M, Kato M, Shimada H. Toxicity of quinolone antimicrobial agents. Journal of Toxicology and Environmental Health 1995; 45: 1-45.
11. Vormann J et al. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcified Tissue International 1997; 61: 230-238.
12. Schaad UB. Use of quinolones in paediatrics. Drug 1993; 45 (Suppl 3): 37-41.
13. Schluter G. Ciprofloxacin: Review of potential toxicologic effects. American Journal of Medicine 1987; 82 (Suppl 4A): 91-93.
14. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients. Infection 1993; 21: 413-421.
15. Schaad UD, Wdgwood-Krucko J. Nalidixic acid in children: Retrospective matched controlled study for cartilage toxicity. Infection 1987; 15: 165-168.
16. Davis R, Markham A, Balfour JA. Ciprofloxacin: An updated review of it's pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019-1074.
17. Physicians' Desk Reference. Medical Economics Co Inc, 47th Edition. Montvale, NJ. 1993.
18. Machida M et al. Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicology and Applied Pharmacology 1990; 105: 403-412.
19. Swanson BN, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrobial Agents and Chemotherapy 1983; 23: 284-288.
20. Imai S, et al. Subacute oral toxicity study on fleroxacin in rats. Chemotherapy 1990; 38 (Suppl 2): S145-S174.
21. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. American Journal of Medicine 1991; 91 (Suppl 6A): 153S-161A.
22. Christ W, Lehnert T. Toxicity of the quinolones. In: (eds. Ciporin C, Heifetz CL & Domagala JM).The new generation quinolones Marcel Dekker Inc, New York, 1990, pp 165-187.
23. Arcieri G, et al. Ciprofloxacin: An update on clinical experience. American Journal of Medicine 1987; 82 (Suppl 4A): 381-386.
24. Gerritsen WR, Peters A, Henny FC, Brouwers JRBJ. Ciprofloxacin-induced nephrotoxicity. Nephrology, Dialysis, Transplantation 1987; 2: 382-383.
25. Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral Ciprofloxacin therapy: A presentation of three cases and a review of the literature. Clinical Nephrology 1989; 32: 75-78.
26. Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundamental and Applied Toxicology 1988; 11: 110-119.
27. Shimo T, Matsuda K, Saito A, Yamazaki M. Arthrotoxicity study of NY-198 in rats. Chemotherapy 1988; 36 (Suppl 2): 439-448.
28. Stahlmann R et al. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Archives of Toxicology 1990; 64, 193-204.
29. Takemoto Y et al. Toxicological studies of AT-2266. II. Subacute and chronic toxicity studies in rats. Chemotherapy 1984; 32 (Suppl 3): 199-220.